Aardvark Therapeutics (AARD) Other Non-Current Assets (2024 - 2026)

Aardvark Therapeutics has reported Other Non-Current Assets for 3 years, with the latest figure at $4.7 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 157.24% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 157.24% YoY) and the FY2025 annual result came in at $4.9 million, up 87.48% from the prior year.
• Other Non-Current Assets eased to $4.7 million in Q1 2026 per AARD's latest filing, from $4.9 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $4.9 million in Q4 2025 and troughed at $1.8 million in Q1 2025.
• A 3-year average of $3.3 million and a median of $3.1 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets jumped 87.48% in 2025, then surged 157.24% in 2026.
• Over 3 years, Other Non-Current Assets stood at $2.6 million in 2024, then surged by 87.48% to $4.9 million in 2025, then retreated by 4.03% to $4.7 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.7 million, $4.9 million, and $3.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.